Spaltudaq now Theraclone, announces HIV findings |
Connect with TechFlash on our Facebook page for all the latest technology news headlines and commentary, plus information and access to special events, photos from events, promotions and more.
Today On Techflash
- Amazon falls on world's most valuable brand list; Microsoft at No. 5
- Amazon announces deal with Paramount Pictures
- Group plans protest at Amazon shareholder meeting
- Seattle webcomic The Oatmeal generates Tesla-Edison controversy
- Amazon shareholders met by protesters, company cuts ties with ALEC
- Microsoft Windows Phone tops Apple's iPhone in China
Mass High Tech
Spaltudaq now Theraclone, announces HIV findings
Spaltudaq -- which may have had the hardest name to pronounce in the history of Seattle startups -- has changed its name to Theraclone Sciences. More importantly, the biotech company announced today new research that could be used to "reverse engineer" a vaccine for HIV.
Theraclone is looking to use the neutralizing effects of monoclonal antibodies from patients who have a slow progression of the disease. "Sera from such patient samples often have the ability to neutralize a broad range of HIV viruses, suggesting the possibility of antibodies capable of controlling HIV infection and progression," the company wrote in a release.
A product of the Seattle biotech incubator Accelerator, Theraclone raised $29 million in venture funding in 2007. Its backers include ARCH Venture Partners, Canaan Partners and Healthcare Ventures.
When the company started, it was looking at developing therapeutic antibodies for cancer.
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
